Recently, an anti-IL-6 monoclonal antibody was shown to decrease inflammation markers and improve anemia in a subgroup of hemodialysis patients with elevated circulating IL6 due to a genetic tendency28. This evidence concerns the gene IL6 and anemia (phenotype).